ECSP13012712A - Mutantes fc de anticuerpos resistentes a proteasas activas - Google Patents

Mutantes fc de anticuerpos resistentes a proteasas activas

Info

Publication number
ECSP13012712A
ECSP13012712A ECSP13012712A ECSP13012712A EC SP13012712 A ECSP13012712 A EC SP13012712A EC SP13012712 A ECSP13012712 A EC SP13012712A EC SP13012712 A ECSP13012712 A EC SP13012712A
Authority
EC
Ecuador
Prior art keywords
mutants
active proteases
containing molecules
antibodies resistant
antibodies
Prior art date
Application number
Other languages
English (en)
Inventor
William Strohl
Randall Brezski
Robert Jordan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of ECSP13012712A publication Critical patent/ECSP13012712A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El anticuerpo monoclonal y otras moléculas que contienen Fc se pueden construir por medio del uso de las variaciones descritas en la región Fc que provocan un aumento de la resistencia a las proteasas derivadas de los huéspedes y patógenos y exhiben la capacidad para interactuar con los receptores Fc? e iniciar la citotoxicidad dirigida por el complemento como se demostró por los ensayos funcionales. Las moléculas que contienen Fc son útiles en el tratamiento de diversas enfermedades y trastornos, en donde las funciones del huésped impulsadas por el FcR aportan la actividad.
ECSP13012712 2010-12-23 2013-06-21 Mutantes fc de anticuerpos resistentes a proteasas activas ECSP13012712A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201061426619P 2010-12-23 2010-12-23
US201161540882P 2011-09-29 2011-09-29
PCT/US2011/065174 WO2012087746A1 (en) 2010-12-23 2011-12-15 Active protease-resistant antibody fc mutants
US13/555,334 US8871204B2 (en) 2010-12-23 2012-07-23 Active protease-resistant antibody FC mutants

Publications (1)

Publication Number Publication Date
ECSP13012712A true ECSP13012712A (es) 2013-08-30

Family

ID=46314374

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012712 ECSP13012712A (es) 2010-12-23 2013-06-21 Mutantes fc de anticuerpos resistentes a proteasas activas

Country Status (33)

Country Link
US (2) US8871204B2 (es)
EP (1) EP2654780B1 (es)
JP (1) JP6012624B2 (es)
KR (1) KR101900280B1 (es)
CN (1) CN103260640B (es)
AU (1) AU2011349719B2 (es)
BR (1) BR112013018317A2 (es)
CA (1) CA2822366A1 (es)
CO (1) CO6741179A2 (es)
CR (1) CR20130292A (es)
CY (1) CY1118923T1 (es)
DK (1) DK2654780T3 (es)
EA (1) EA028658B1 (es)
EC (1) ECSP13012712A (es)
ES (1) ES2623912T3 (es)
GT (1) GT201300167A (es)
HR (1) HRP20170595T1 (es)
HU (1) HUE033205T2 (es)
IL (1) IL226987A (es)
LT (1) LT2654780T (es)
MX (1) MX347077B (es)
MY (1) MY162489A (es)
NI (1) NI201300057A (es)
NZ (1) NZ612379A (es)
PH (1) PH12013501332B1 (es)
PL (1) PL2654780T3 (es)
PT (1) PT2654780T (es)
RS (1) RS55906B1 (es)
SG (1) SG191233A1 (es)
SI (1) SI2654780T1 (es)
SM (1) SMT201700201T1 (es)
WO (1) WO2012087746A1 (es)
ZA (1) ZA201305538B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095478A1 (en) 2008-01-31 2009-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
EP2654780B1 (en) * 2010-12-23 2017-02-01 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
IL312872A (en) 2011-06-28 2024-07-01 Inhibrx Inc Methods for purifying fusion proteins containing serphin
CA2862101A1 (en) 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
US10865243B2 (en) * 2014-07-16 2020-12-15 Hinrich Abken Chimeric antigen receptor and its use
CN104177496B (zh) * 2014-09-02 2015-03-11 安源生物科技(上海)有限公司 人IgG2抗体铰链区修饰体
KR102536786B1 (ko) 2014-10-10 2023-05-26 이나뜨 파르마 에스.에이. Ｃｄ７３ 차단
JP6737781B2 (ja) * 2014-10-27 2020-08-12 インヒブルクス，インコーポレイティド セルピン融合ポリペプチド及びその使用方法
AU2015350075B2 (en) 2014-11-17 2021-06-03 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using CD3xCD20 bispecific antibody
EP3259288A1 (en) 2015-02-20 2017-12-27 Innate Pharma Cd73 blockade
US10196445B1 (en) 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
EP3302532A4 (en) 2015-06-05 2019-01-09 New York University COMPOSITIONS AND METHODS FOR BIOLOGICAL ACTIVE AGGREGATES AGAINST STAPHYLOKOKEN
FI3325011T6 (fi) 2015-07-24 2023-05-11 Ihmisen proteiinifragmenttien fuusioproteiineja järjestyksenmukaisesti multimerisoitujen, paremmin komplementtia sitovien immunoglobuliini-fc-koostumusten muodostamiseksi
KR20180030917A (ko) 2015-08-05 2018-03-26 얀센 바이오테크 인코포레이티드 항-cd154 항체 및 그의 사용 방법
TWI784917B (zh) 2015-09-23 2022-11-21 美商再生元醫藥公司 最優化抗ｃｄ３雙特異性抗體及其用途
US20190048089A1 (en) 2015-09-30 2019-02-14 Janssen Biotech, Inc. Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
AU2016341400B2 (en) * 2015-10-23 2021-04-08 Apogenix Ag Single-chain CD137-receptor agonist proteins
ES2972740T3 (es) 2016-03-02 2024-06-14 Momenta Pharmaceuticals Inc Procedimientos relacionados con construcciones de Fc modificadas genéticamente
WO2017157948A1 (en) 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
BR112018068678A2 (pt) 2016-03-15 2019-01-15 Innate Pharma anticorpos anti-mica
PL3484514T3 (pl) 2016-05-23 2024-04-29 Momenta Pharmaceuticals, Inc. Kompozycje i sposoby związane z projektowanymi konstruktami Fc
CN107474136B (zh) * 2016-06-08 2023-03-07 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
KR102584011B1 (ko) 2017-03-16 2023-09-27 이나뜨 파르마 에스.에이. 암 치료를 위한 조성물 및 방법
CN113201071A (zh) * 2017-03-28 2021-08-03 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
CN111405910A (zh) * 2017-05-10 2020-07-10 阿尔巴朱纳治疗有限公司 具有高HIV抗病毒和免疫调节双重活性的Fc融合蛋白衍生物
RS61883B1 (sr) 2017-09-19 2021-06-30 Tillotts Pharma Ag Varijante antitela
PT3807316T (pt) 2018-06-18 2024-07-29 Innate Pharma Composições e métodos para tratamento de cancro
IL280875B2 (en) 2018-08-31 2024-12-01 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
US20220002370A1 (en) 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
EP3711772A1 (en) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
CN113874392B (zh) * 2019-03-28 2025-10-21 丹尼斯科美国公司 工程化抗体
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
CN114729058B (zh) * 2019-08-23 2025-08-01 希望之城 IgG抗体组合物和其制备方法
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
IL300260A (en) * 2020-08-07 2023-03-01 Genentech Inc FLT3 ligand fusion proteins and methods of use
TW202235431A (zh) 2020-11-25 2022-09-16 美商艾希利歐發展股份有限公司 腫瘤特異性可裂解連接子
EP4288080A1 (en) * 2021-02-04 2023-12-13 Helsingin Yliopisto A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto
CN117597365A (zh) * 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
US20250145730A1 (en) * 2021-12-16 2025-05-08 Shanghai Bao Pharmaceuticals Co., Ltd. Anti-immunoglobulin degrading enzyme-digested fc variant
CN120677180A (zh) 2022-11-18 2025-09-19 赛斯米克治疗公司 Fc融合分子及其用途
KR20250170709A (ko) 2023-01-06 2025-12-05 사이즈믹 테라퓨틱, 인코포레이티드. 프로테아제 변이체 및 이의 용도
CN121517545A (zh) * 2024-08-13 2026-02-13 菲鹏生物股份有限公司 一种Fc突变体及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
EP1082137A4 (en) 1998-05-06 2004-05-19 Univ Temple REVERSE OF PERCENTAL RESPONSE BY INTERRUPTING THE MACROPHAGE RECEPTOR FcSg (g) RI
KR101077001B1 (ko) * 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7129331B2 (en) 2000-05-31 2006-10-31 Pestka Biomedical Laboratories, Inc. Phosphorylated polypeptides and uses related thereto
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
JP2009526746A (ja) 2005-08-19 2009-07-23 セントカー・インコーポレーテツド タンパク質分解抵抗性の抗体調製物
AU2006299429B2 (en) * 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
KR101588276B1 (ko) * 2007-08-10 2016-01-26 센토코 오르토 바이오테크 인코포레이티드 질환 표시자로서의 면역글로불린 절단 단편, 및 그의 검출 및 결합을 위한 조성물
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
WO2009045894A1 (en) 2007-09-28 2009-04-09 Centocor, Inc. Methods and structural conformations of antibody preparations with increased resistance to proteases
DK2211904T3 (en) * 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
JP2012524545A (ja) 2009-04-21 2012-10-18 アムジェン インコーポレイテッド 断片化耐性ＩｇＧ１Ｆｃ−コンジュゲート
EP2654780B1 (en) * 2010-12-23 2017-02-01 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
US8729985B2 (en) 2012-01-23 2014-05-20 Electro-Mechanical Corporation Switchgear visible disconnect mechanical interlock

Also Published As

Publication number Publication date
MX347077B (es) 2017-04-10
US8871204B2 (en) 2014-10-28
PH12013501332B1 (en) 2019-01-16
WO2012087746A1 (en) 2012-06-28
MX2013007291A (es) 2013-09-13
US20130011386A1 (en) 2013-01-10
GT201300167A (es) 2014-09-26
SG191233A1 (en) 2013-07-31
BR112013018317A2 (pt) 2017-03-21
EP2654780B1 (en) 2017-02-01
ZA201305538B (en) 2015-01-28
US20150139984A1 (en) 2015-05-21
CA2822366A1 (en) 2012-06-28
PT2654780T (pt) 2017-04-06
HUE033205T2 (en) 2017-11-28
EP2654780A4 (en) 2015-03-18
MY162489A (en) 2017-06-15
RS55906B1 (sr) 2017-09-29
PH12013501332A1 (en) 2013-08-28
CN103260640A (zh) 2013-08-21
KR20140003485A (ko) 2014-01-09
ES2623912T3 (es) 2017-07-12
SI2654780T1 (sl) 2017-06-30
AU2011349719B2 (en) 2016-09-15
NI201300057A (es) 2014-02-25
HRP20170595T1 (hr) 2017-06-16
CY1118923T1 (el) 2018-01-10
JP6012624B2 (ja) 2016-10-25
PL2654780T3 (pl) 2017-07-31
AU2011349719A1 (en) 2013-07-04
NZ612379A (en) 2014-10-31
EP2654780A1 (en) 2013-10-30
SMT201700201T1 (it) 2017-05-08
CR20130292A (es) 2013-10-03
CN103260640B (zh) 2015-12-02
IL226987A (en) 2017-07-31
DK2654780T3 (en) 2017-04-10
KR101900280B1 (ko) 2018-11-08
US9611328B2 (en) 2017-04-04
JP2014504301A (ja) 2014-02-20
CO6741179A2 (es) 2013-08-30
EA201390958A1 (ru) 2013-11-29
EA028658B1 (ru) 2017-12-29
LT2654780T (lt) 2017-03-27

Similar Documents

Publication Publication Date Title
ECSP13012712A (es) Mutantes fc de anticuerpos resistentes a proteasas activas
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
CO2017002719A2 (es) Anticuerpos anti-glucagón
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
CR20160570A (es) Anticuerpos anti-pld1 y su uso para mejorar la función de las celulas t
CR20120086A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
PA8849001A1 (es) Anticuerpos de c-met
PE20150002A1 (es) Anticuerpos anti-fcrn
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
AR083044A1 (es) Anticuerpos anti-cd48 y usos de los mismos
GT201400162A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
MX376058B (es) Uso de peptidos glp-1 de accion prolongada.
AR091305A1 (es) ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
MX421100B (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
PE20170192A1 (es) Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
MX2016002166A (es) Anticuerpos.
DOP2018000019A (es) Inmunoconjugados de il22
MX2015016304A (es) Proteinas de union al antigeno del receptor de oncostatina m.
DOP2016000027A (es) Moduladores benzoimidazol-2-ilpirimidinas del receptor h4 de histamina
MX379312B (es) Anticuerpos especificos para fcrn.